Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
作者信息
Azad Arun A, Chi Kim N
机构信息
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
出版信息
Eur Urol. 2015 Sep;68(3):e57-8. doi: 10.1016/j.eururo.2015.03.042. Epub 2015 Apr 8.
PMID:25864159
Abstract
摘要
相似文献
1
Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
Eur Urol. 2015 Sep;68(3):e57-8. doi: 10.1016/j.eururo.2015.03.042. Epub 2015 Apr 8.
2
Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
Eur Urol. 2015 Sep;68(3):e55-6. doi: 10.1016/j.eururo.2015.03.043. Epub 2015 Apr 10.
3
Burden of disease matters when it comes to systemic therapy for prostate cancer.
Eur Urol. 2015 Mar;67(3):448-50. doi: 10.1016/j.eururo.2014.02.032. Epub 2014 Feb 22.
4
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.阿比特龙在体能状态差的转移性去势抵抗性前列腺癌患者中的疗效。
Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31.
5
Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.
6
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23.
7
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.醋酸阿比特龙治疗初治转移性去势抵抗性前列腺癌患者时骨靶向治疗的影响：研究COU-AA-302的事后分析
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
8
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?获批之外：在转移性去势抵抗性前列腺癌中使用不断扩充的治疗手段的最恰当方式是什么，以及我们该如何推进？
Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13.
9
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.化疗在醋酸阿比特龙治疗后进展的转移性去势抵抗性前列腺癌患者治疗中的作用
Cancer Chemother Pharmacol. 2015 Sep;76(3):439-45. doi: 10.1007/s00280-015-2803-y. Epub 2015 Jun 17.
10
Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.对伯纳德·通巴尔致编辑的信的回复，信的主题为：亚历山德罗·夏拉、佩尔·安德斯·亚伯拉罕松、毛里齐奥·布劳西等人所著《前列腺癌的间歇性雄激素剥夺疗法：聚焦于3期试验的批判性综述》。《欧洲泌尿外科杂志》2013年；第64卷：722 - 730页
Eur Urol. 2014 Apr;65(4):e57. doi: 10.1016/j.eururo.2013.12.015. Epub 2013 Dec 21.
Zotero 插件